FCGR2A Promoter Methylation and Risks for Intravenous Immunoglobulin Treatment Responses in Kawasaki Disease
Kawasaki disease (KD) is characterized by pediatric systemic vasculitis of an unknown cause. The low affinity immunoglobulin gamma Fc region receptor II-a (FCGR2A) gene was reported to be involved in the susceptibility of KD. DNA methylation is one of the epigenetic mechanisms that control gene expr...
Saved in:
| Main Authors: | , , , , , , , , , |
|---|---|
| Format: | Article |
| Language: | English |
| Published: |
Wiley
2015-01-01
|
| Series: | Mediators of Inflammation |
| Online Access: | http://dx.doi.org/10.1155/2015/564625 |
| Tags: |
Add Tag
No Tags, Be the first to tag this record!
|
| _version_ | 1849307254951510016 |
|---|---|
| author | Ho-Chang Kuo Yu-Wen Hsu Mei-Shin Wu Peng Yeong Woon Henry Sung-Ching Wong Li-Jen Tsai Ruo-Kai Lin Sukhontip Klahan Kai-Sheng Hsieh Wei-Chiao Chang |
| author_facet | Ho-Chang Kuo Yu-Wen Hsu Mei-Shin Wu Peng Yeong Woon Henry Sung-Ching Wong Li-Jen Tsai Ruo-Kai Lin Sukhontip Klahan Kai-Sheng Hsieh Wei-Chiao Chang |
| author_sort | Ho-Chang Kuo |
| collection | DOAJ |
| description | Kawasaki disease (KD) is characterized by pediatric systemic vasculitis of an unknown cause. The low affinity immunoglobulin gamma Fc region receptor II-a (FCGR2A) gene was reported to be involved in the susceptibility of KD. DNA methylation is one of the epigenetic mechanisms that control gene expression; thus, we hypothesized that methylation status of CpG islands in FCGR2A promoter associates with the susceptibility and therapeutic outcomes of Kawasaki disease. In this study, 36 KD patients and 24 healthy subjects from out-patient clinic were recruited. Eleven potential methylation sites within the targeted promoter region of FCGR2A were selected for investigation. We marked the eleven methylation sites from A to K. Our results indicated that methylation at the CpG sites G, H, and J associated with the risk of KD. CpG sites B, C, E, F, H, J, and K were found to associate with the outcomes of IVIG treatment. In addition, CpG sites G, J, and K were predicted as transcription factors binding sites for NF-kB, Myc-Max, and SP2, respectively. Our study reported a significant association among the promoter methylation of FCGR2A, susceptibility of KD, and the therapeutic outcomes of IVIG treatment. The methylation levels of CpG sites of FCGR2A gene promoter should be an important marker for optimizing IVIG therapy. |
| format | Article |
| id | doaj-art-271e235adba34643b1efd5b81d9babdd |
| institution | Kabale University |
| issn | 0962-9351 1466-1861 |
| language | English |
| publishDate | 2015-01-01 |
| publisher | Wiley |
| record_format | Article |
| series | Mediators of Inflammation |
| spelling | doaj-art-271e235adba34643b1efd5b81d9babdd2025-08-20T03:54:48ZengWileyMediators of Inflammation0962-93511466-18612015-01-01201510.1155/2015/564625564625FCGR2A Promoter Methylation and Risks for Intravenous Immunoglobulin Treatment Responses in Kawasaki DiseaseHo-Chang Kuo0Yu-Wen Hsu1Mei-Shin Wu2Peng Yeong Woon3Henry Sung-Ching Wong4Li-Jen Tsai5Ruo-Kai Lin6Sukhontip Klahan7Kai-Sheng Hsieh8Wei-Chiao Chang9Department of Pediatrics and Kawasaki Disease Center, Kaohsiung Chang Gung Memorial Hospital and Chang Gung University College of Medicine, Kaohsiung 80031, TaiwanDepartment of Clinical Pharmacy, College of Pharmacy, Taipei Medical University, Taipei 11696, TaiwanDepartment of Clinical Pharmacy, College of Pharmacy, Taipei Medical University, Taipei 11696, TaiwanDepartment of Molecular Biology and Human Genetics, Tzu Chi University, Hualien 97004, TaiwanMaster Program for Clinical Pharmacogenomics and Pharmacoproteomics, School of Pharmacy, Taipei Medical University, Taipei 11696, TaiwanGraduate Institute of Medical Sciences, College of Medicine, Taipei Medical University, Taipei 11696, TaiwanGraduate Institute of Pharmacognosy, Taipei Medical University, Taipei 11696, TaiwanDepartment of Clinical Pharmacy, College of Pharmacy, Taipei Medical University, Taipei 11696, TaiwanDepartment of Pediatrics and Kawasaki Disease Center, Kaohsiung Chang Gung Memorial Hospital and Chang Gung University College of Medicine, Kaohsiung 80031, TaiwanDepartment of Clinical Pharmacy, College of Pharmacy, Taipei Medical University, Taipei 11696, TaiwanKawasaki disease (KD) is characterized by pediatric systemic vasculitis of an unknown cause. The low affinity immunoglobulin gamma Fc region receptor II-a (FCGR2A) gene was reported to be involved in the susceptibility of KD. DNA methylation is one of the epigenetic mechanisms that control gene expression; thus, we hypothesized that methylation status of CpG islands in FCGR2A promoter associates with the susceptibility and therapeutic outcomes of Kawasaki disease. In this study, 36 KD patients and 24 healthy subjects from out-patient clinic were recruited. Eleven potential methylation sites within the targeted promoter region of FCGR2A were selected for investigation. We marked the eleven methylation sites from A to K. Our results indicated that methylation at the CpG sites G, H, and J associated with the risk of KD. CpG sites B, C, E, F, H, J, and K were found to associate with the outcomes of IVIG treatment. In addition, CpG sites G, J, and K were predicted as transcription factors binding sites for NF-kB, Myc-Max, and SP2, respectively. Our study reported a significant association among the promoter methylation of FCGR2A, susceptibility of KD, and the therapeutic outcomes of IVIG treatment. The methylation levels of CpG sites of FCGR2A gene promoter should be an important marker for optimizing IVIG therapy.http://dx.doi.org/10.1155/2015/564625 |
| spellingShingle | Ho-Chang Kuo Yu-Wen Hsu Mei-Shin Wu Peng Yeong Woon Henry Sung-Ching Wong Li-Jen Tsai Ruo-Kai Lin Sukhontip Klahan Kai-Sheng Hsieh Wei-Chiao Chang FCGR2A Promoter Methylation and Risks for Intravenous Immunoglobulin Treatment Responses in Kawasaki Disease Mediators of Inflammation |
| title | FCGR2A Promoter Methylation and Risks for Intravenous Immunoglobulin Treatment Responses in Kawasaki Disease |
| title_full | FCGR2A Promoter Methylation and Risks for Intravenous Immunoglobulin Treatment Responses in Kawasaki Disease |
| title_fullStr | FCGR2A Promoter Methylation and Risks for Intravenous Immunoglobulin Treatment Responses in Kawasaki Disease |
| title_full_unstemmed | FCGR2A Promoter Methylation and Risks for Intravenous Immunoglobulin Treatment Responses in Kawasaki Disease |
| title_short | FCGR2A Promoter Methylation and Risks for Intravenous Immunoglobulin Treatment Responses in Kawasaki Disease |
| title_sort | fcgr2a promoter methylation and risks for intravenous immunoglobulin treatment responses in kawasaki disease |
| url | http://dx.doi.org/10.1155/2015/564625 |
| work_keys_str_mv | AT hochangkuo fcgr2apromotermethylationandrisksforintravenousimmunoglobulintreatmentresponsesinkawasakidisease AT yuwenhsu fcgr2apromotermethylationandrisksforintravenousimmunoglobulintreatmentresponsesinkawasakidisease AT meishinwu fcgr2apromotermethylationandrisksforintravenousimmunoglobulintreatmentresponsesinkawasakidisease AT pengyeongwoon fcgr2apromotermethylationandrisksforintravenousimmunoglobulintreatmentresponsesinkawasakidisease AT henrysungchingwong fcgr2apromotermethylationandrisksforintravenousimmunoglobulintreatmentresponsesinkawasakidisease AT lijentsai fcgr2apromotermethylationandrisksforintravenousimmunoglobulintreatmentresponsesinkawasakidisease AT ruokailin fcgr2apromotermethylationandrisksforintravenousimmunoglobulintreatmentresponsesinkawasakidisease AT sukhontipklahan fcgr2apromotermethylationandrisksforintravenousimmunoglobulintreatmentresponsesinkawasakidisease AT kaishenghsieh fcgr2apromotermethylationandrisksforintravenousimmunoglobulintreatmentresponsesinkawasakidisease AT weichiaochang fcgr2apromotermethylationandrisksforintravenousimmunoglobulintreatmentresponsesinkawasakidisease |